Week in Review | Lilly's Retatrutide Dose Data, Novartis' RNA Deal & Jaypirca's Approval

Lilly's retatrutide detail reveals that adverse-event discontinuations peaked below the top dose, while Jaypirca gains first-line CLL and SLL approval for adults without a known 17p deletion. Novartis agrees to $575 million upfront for Abogen's autoimmune RNA program, and Sanofi-Regeneron expands its long-acting antibody partnership. Ovarian-cancer datasets, Mirum's hepatitis D results and uniQure's Huntington's filing show why patient populations and control groups matter. CMS rebates and medicine tariffs reach manufacturer economics, alongside retina, respiratory and rare-disease updates.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.